Page last updated: 2024-12-06

ruthenium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ruthenium is a hard, brittle, silvery-white transition metal. It is a member of the platinum group and is found in nature in trace amounts. Ruthenium is highly resistant to corrosion and is used in various applications, including electrical contacts, alloys, and catalysts. It is also used in the production of some pharmaceuticals and in the development of new materials with unique properties. Ruthenium compounds are known for their catalytic activity and have been extensively studied for their potential use in a wide range of applications, including organic synthesis, oxidation reactions, and water splitting. The synthesis of ruthenium compounds can involve various methods, including the reduction of ruthenium salts or the reaction of ruthenium oxides with other compounds. The effects of ruthenium compounds vary depending on their specific structure and the reaction conditions. For instance, some ruthenium compounds have been shown to exhibit anticancer activity, while others have been used in the development of new drugs. The importance of ruthenium compounds lies in their versatility and potential for applications in various fields. Ruthenium compounds are studied for their unique properties, including their catalytic activity, reactivity, and ability to form stable complexes. Researchers are exploring the use of ruthenium compounds in the development of new technologies, such as solar cells, fuel cells, and sensors.'

Ruthenium: A hard, brittle, grayish-white rare earth metal with an atomic symbol Ru, atomic number 44, and atomic weight 101.07. It is used as a catalyst and hardener for PLATINUM and PALLADIUM. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23950
CHEBI ID30682
MeSH IDM0019313

Synonyms (95)

Synonym
rutherium black
44ru
rutenio
ruthenium
7440-18-8
ruthenium atom
RU ,
CHEBI:30682
ruthenium ion
ruthenium, powder, 99.99% trace metals basis
ruthenium on alumina, extent of labeling: 5 wt. % loading, powder, reduced, dry
ruthenium, powder, -200 mesh, 99.9% trace metals basis
ruthenium, sponge, -100 mesh, 99.9% trace metals basis
ruthenium on carbon, extent of labeling: 5 wt. % loading
ruthenium on alumina, extent of labeling: 5 wt. % loading, powder, degussa type h213 r/d
ruthenium on alumina, extent of labeling: 0.5 wt. % loading, pellets, 3.2 mm
ruthenium black
R0076
A838114
ruthenium alumina
AKOS015924307
7ui0tkc3u5 ,
ccris 9434
unii-7ui0tkc3u5
einecs 231-127-1
ruthenium [mi]
ruthenium metal
ruthenium on carbon
rutheniumon carbon
ru on alumina
ruthenium-on-carbon
ruthenium/carbon
KJTLSVCANCCWHF-UHFFFAOYSA-N
ruthenium/silica
ru/c
ruthenium on alumina
ru on carbon
ruthenium-alumina
DTXSID9064687 ,
ruthenium powder, -200 mesh
ruthenium powder, -200 mesh, premion?
ruthenium, 4% on 6.35mm (0.25in) alumina rings
ruthenium powder, -325 mesh
ruthenium, 0.5% on granular carbon
ruthenium powder, -22 mesh, premion
ruthenium sponge, -20 mesh
ruthenium, 2% on 3.18mm (0.125in) alumina pellets
ruthenium standard for aas, analytical standard, ready-to-use, in hydrochloric acid
mfcd00011207
mfcd03458417
ruthenium powder, 99.99%, 4n
ruthenium, 0.5% on alumina
ruthenium, 5% on carbon
ruthenium black, 99.9%, 3n
ruthenium, 0.5% on carbon
ruthenium powder, 3n5
ruthenium powder, 3n
ruthenium, 5% on alumina
ruthenium powder, 99.9%, 3n
ruthenium, ruthenium, foil, 10x10mm, thickness 1.0mm, 99.9%
ruthenium, lump, 10 mm max. lump size, weight 2.5 g, purity 99.9%
ruthenium, powder, max. particle size 850 micron, weight 2 g, purity 99.9%
ruthenium, powder, max. particle size 450 micron, weight 5 g, purity 99.9%
ruthenium, ruthenium, bar, 25mm x 2mm x 2mm, 99.9%
ruthenium, ruthenium, rod, 12.7mm, diameter 12.7mm, 99.9%
ruthenium, ruthenium, microfoil, disks, 10mm, thinness 0.1mum, specific density 122mug/cm2, permanent mylar 3.5mum support, 99.9%
ruthenium, powder, max. particle size 450 micron, weight 1 g, purity 99.9%
ruthenium, powder, 850 max. part. size (micron), weight 5 g, purity 99.9%
ruthenium, ruthenium, pellets, 5g, max. size 10mm, 99.9%
ruthenium, ruthenium, pellets, 2.5g, max. size 10mm, 99.9%
ruthenium, ruthenium, foil, 25x25mm, thickness 1.0mm, 99.9%
ruthenium, ruthenium, foil, 6x6mm, thickness 1.0mm, 99.9%
ruthenium, ruthenium, bar, 50mm x 2mm x 2mm, 99.9%
ruthenium, powder, max. particle size 450 micron, weight 10 g, purity 99.9%
ruthenium, powder, 850 max. part. size (micron), weight 1 g, purity 99.9%
ruthenium, ruthenium, microfoil, disks, 10mm, thinness 0.025mum, specific density 30.5mug/cm2, permanent mylar 3.5mum support, 99.9%
ruthenium, powder, max. particle size 450 micron, weight 2 g, purity 99.9%
ruthenium, powder, max. particle size 850 micron, weight 10 g, purity 99.9%
ruthenium 5% on carbon
CS-0035137
HY-W020867
ruthenium 5% on carbon (wetted with ca. 50% water)
ruthenium nanofoil
ruthenium nanorods
ruthenium pentahydride
ruthenium single crystal, 9-10mm (0.35-0.39in) dia, 50mm (2.0in) long, (0001) orientation
Q1086
ruthenium nanowires
lead fluoride (pbf2) sputtering targets
5% ruthenium on carbon
ruthenium, powder 20 mesh
dtxcid1047651
ruthenium standard: ru @ 10000 microg/ml in 20% hcl
ruthenium standard: ru @ 1000 microg/ml in 20% hcl
ruthenium - ru @ 1000 microg/ml in 20% hcl

Research Excerpts

Overview

Ruthenium (Ru) is a transition metal of the platinum group, with potentially less toxicity than platinum drugs. Ruthenium red is an inhibitor of calcium uptake by mitochondria, increases the spontaneous transmitter release but decreases the quantal content.

ExcerptReferenceRelevance
"Ruthenium complex is an important compound group for antitumor drug research and development. "( Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy.
Le, Q; Lu, Y; Wang, W; Wang, Y; Zhu, D, 2022
)
3.61
"Ruthenium is a metal that has unique characteristics and important in vivo and in vitro results achieved for cancer treatment."( The trans-[Ru(PPh
Batista, AA; Becceneri, AB; Castellano, EE; Cominetti, MR; Maistro, EL; Plutin, AM; Popolin, CP, 2018
)
1.2
"Ruthenium is a transition metal that possesses several advantages for rational antitumor drug design and biological applications."( Cytoxicity and apoptotic mechanism of ruthenium(II) amino acid complexes in sarcoma-180 tumor cells.
Almeida, MA; Batista, AA; de Paula Silveira-Lacerda, E; Delella, FK; Felisbino, SL; Lima, AP; Mello, FM; Moreno, V; Pereira, FC; Pinto, TM; Pires, WC, 2014
)
1.39
"Ruthenium seems to be a valuable candidate for the design of NO-donating and CO-donating molecules. "( Ruthenium-based nitric oxide-donating and carbon monoxide-donating molecules.
Boydens, C; Pauwels, B; Van de Voorde, J; Vanden Daele, L, 2016
)
3.32
"Ruthenium (Ru) is a transition metal of the platinum group, with potentially less toxicity than platinum drugs."( Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes.
Bark, Y; Carter, R; Gallevo, CR; Habtemariam, A; Menezes, N; Romero, MJ; Sadler, PJ; Sharma, RA; Westhorpe, A, 2016
)
1.4
"Ruthenium complex is a potentially theranostic agent for cancer imaging and therapy, however its application is limited due to poor water-solubility and lack of tumor selectivity. "( A pH-Sensitive Nanocarrier for Tumor Targeting : Delivery of Ruthenium Complex for Tumor Theranostic by pH-Sensitive Nanocapsule.
Chen, L; Deng, Y; Fu, A; Fu, C; Wu, W, 2016
)
2.12
"3. Ruthenium red, which is an inhibitor of calcium uptake by mitochondria, increases the spontaneous transmitter release but decreases the quantal content."( On the role of mitochondria in transmitter release from motor nerve terminals.
Alnaes, E; Rahamimoff, R, 1975
)
0.77
"Ruthenium red is a widely used method for retaining and localizing proteoglycan for electron microscopy but its inability to produce sufficient density within the cells for light microscopy prevented simultaneous visualization by these two modes."( The use of ruthenium and p-phenylenediamine to stain cartilage simultaneously for light and electron microscopy.
Mitchell, N; Shepard, N, 1977
)
1.37
"Ruthenium red is a well-known and effective inhibitor of the mitochondrial Ca2+ uniporter; however, Reed and Bygrave [(1974) FEBS Lett. "( Inhibition of mitochondrial calcium ion transport by an oxo-bridged dinuclear ruthenium ammine complex.
Clarke, MJ; Emerson, J; Sanadi, DR; Ying, WL, 1991
)
1.95
"Ruthenium red is an inhibitor of Ca2+ translocation and Bay K-8644 is a Ca2+-channel agonist."( Mitotic progression in stamen hair cells of Tradescantia is accelerated by treatment with ruthenium red and Bay K-8644.
Chen, TL; Wolniak, SM, 1987
)
1.22

Effects

Ruthenium metal complex has been shown to exert several chemical and biological activities. Ruthenium complexes have been studied as potential alternatives to platinum-type anticancer drugs due to their unique medical properties.

ExcerptReferenceRelevance
"Ruthenium complexes have been shown to be potential promising alternatives to these metal-based drugs."( Ruthenium(II) Polypyridyl Complexes Containing Simple Dioxo Ligands: a Structure-Activity Relationship Study Shows the Importance of the Charge.
Alessio, E; Burckel, P; Gandioso, A; Gasser, G; Vidal, A, 2022
)
2.89
"Ruthenium complexes have been widely studied as potential alternatives to platinum-type anticancer drugs due to their unique medical properties such as high selectivity, strong ability to inhibit solid tumour metastasis. "( Dual drug delivery system of RAPTA-C and paclitaxel based on fructose coated nanoparticles for metastatic cancer treatment.
Hong, Y; Khine, YY; Lu, H; Lu, M; Stenzel, MH; Wang, S; Zheng, J, 2023
)
2.35
"Ruthenium complexes have been investigated for various biological applications by virtue of their radical scavenging, DNA binding, receptor binding, and cytotoxic abilities; especially the possible potential application of these complexes in photodynamic therapy (PDT). "( Structure-based biological investigations on ruthenium complexes containing 2,2'-bipyridine ligands and their applications in photodynamic therapy as a potential photosensitizer.
Basumatary, D; Kaid, SMA; Kullaiah, B; Mahanta, P; Manjasetty, BA; Medhi, C; Puttaswamy, NY; Sarma, P, 2023
)
2.61
"Ruthenium metal complex has been shown to exert several chemical and biological activities. "( Ruthenium derivatives attenuate LPS-induced inflammatory responses and liver injury via suppressing NF-κB signaling and free radical production.
Fong, TH; Hsia, CH; Hsia, CW; Huang, HC; Jayakumar, T; Khamrang, T; Manubolu, M; Sheu, JR; Velusamy, M, 2020
)
3.44
"Ruthenium compounds have been shown to be promising alternatives to platinum(II) drugs. "( Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex.
Azmanova, M; Barry, NPE; Cooper, PA; Pitto-Barry, A; Shnyder, SD; Soldevila-Barreda, JJ, 2020
)
2.24
"Ruthenium complexes have been extensively investigated for their prospective value as alternatives to cisplatin. "( Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools.
Gano, L; Garcia, MH; Gonçalves, MS; Jorge, TF; Marques, F; Martins, M; Matos, AP; Morais, TS; Pinheiro, T; Tomaz, AI; Tortosa, F; Valente, A, 2019
)
1.96
"The ruthenium complex has been purified using a silica chromatographic column by protecting carboxylic acid groups as iso-butyl ester, which are subsequently hydrolyzed."( A simple synthetic route to obtain pure trans-ruthenium(II) complexes for dye-sensitized solar cell applications.
Artuso, E; Barbero, N; Barolo, C; De Angelis, F; Di Censo, D; Fantacci, S; Grätzel, M; Lobello, MG; Nazeeruddin, MK; Viscardi, G; Yum, JH, 2013
)
1.13
"Ruthenium complexes have been considered as promising substitutes for cisplatin in cancer chemotherapy. "( Labile ruthenium(ii) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation.
Chao, H; Chen, Y; Huang, H; Ji, L; Zhang, P, 2015
)
2.31
"Ruthenium compounds have been actively studied as metallodrugs for cancer therapy. "( Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy.
Silva, Dde O, 2010
)
2.09
"The ruthenium(III) has also been determined in presence of several interfering and non-interfering cations, anions and polyaminocarboxylates."( Highly sensitive catalytic spectrophotometric determination of ruthenium.
Naik, RM; Prasad, S; Srivastava, A, 2008
)
1.07
"The ruthenium(III) has also been determined in the presence of several other interfering and non-interfering cations and anions and no foreign ions interfered in the determination of ruthenium(III) up to five-fold higher concentration of the foreign ions tested."( Application of ruthenium catalyzed oxidation of [tris(2-aminoethyl)amine] in trace determination of ruthenium in environmental water samples.
Naik, RM; Prasad, S; Srivastava, A, 2008
)
1.18
"Ruthenium myoglobins have been prepared by the reconstitution of horse heart apomyoglobin with either ruthenium(II) or ruthenium(III) mesoporphyrin IX (MpIX) derivatives. "( Preparation of ruthenium(II) and ruthenium(III) myoglobin and the reaction of dioxygen, and carbon monoxide, with ruthenium(II) myoglobin.
Addison, AW; Dolphin, D; James, BR; Paulson, DR, 1979
)
2.06
"Ruthenium red has recently been found to inhibit the effects of capsaicin on peripheral terminals of sensory neurones. "( The effects of ruthenium red on the response of guinea-pig ileum to capsaicin.
Chahl, LA, 1989
)
2.07

Actions

Ruthenium(II) complexes catalyze the CC coupling of 1,1-disubstituted allenes and fluorinated alcohols to form homoallylic alcohols. Ruthenium was chosen because several Ru compounds have shown promising anticancer activity.

ExcerptReferenceRelevance
"Ruthenium(II) complexes catalyze the CC coupling of 1,1-disubstituted allenes and fluorinated alcohols to form homoallylic alcohols bearing all-carbon quaternary centers with good to complete levels of diastereoselectivity. "( Ruthenium-catalyzed C-C coupling of fluorinated alcohols with allenes: dehydrogenation at the energetic limit of β-hydride elimination.
Krische, MJ; Luong, T; Sam, B, 2015
)
3.3
"Ruthenium was chosen because several Ru compounds have shown promising anticancer activity."( Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity.
Alessio, E; Bratsos, I; Gianferrara, T; Iengo, E; Milani, B; Ostrić, A; Spagnul, C; Zangrando, E, 2009
)
1.37

Treatment

Ruthenium treatment upregulated the marker genes involved in apoptosis and cell cycle progression while it downregulated BRCA1 mRNA and replication of HCC1937 cells. Treatment of a ruthenia acetylide precursor with a series of organic halides produced the corresponding vinylidene complexes 2.

ExcerptReferenceRelevance
"Ruthenium treatment upregulated the marker genes involved in apoptosis and cell cycle progression while it downregulated BRCA1 mRNA and replication of HCC1937 cells."( Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Hansongnern, K; Nhukeaw, T; Ratanaphan, A; Temboot, P, 2014
)
1.32
"Treatment of a ruthenium acetylide precursor containing indenyl and dppe ligands with a series of organic halides produced the corresponding vinylidene complexes 2 in good yield."( Reactivity of ruthenium vinylidene complexes containing indenyl/dppe ligands and unsaturated bonds at Cδ with trimethylsilyl azide.
Cheng, CP; Her, TM; Su, WH; Sung, HL, 2012
)
1.08
"Pretreatment with ruthenium red (100 micromol/L), an antagonist of vanilloid receptor subtype 1 (VR1), blocked the effect of capsaicin on CBA."( Capsaicin facilitates carotid sinus baroreceptor activity in anesthetized rats.
He, RR; Liu, YX; Wang, ZM; Wu, YM; Zhang, H, 2004
)
0.65
"Pretreatment with ruthenium red (2.7--90 mug/ml) for ten minutes reduced 5-hydroxytryptamine and norepinephrine responses in a dose-related manner but did not affect acetylcholine-induced responses."( Effects of ruthenium red and KCL on responses of guinea pig umbilical veins.
Luft, JH; Nair, X; Watson, EL, 1975
)
0.97

Toxicity

Ruthenium is significantly less toxic than Na(2)[Fe(CN)(5)(NO)] (SNP) species. The dye promotes tight binding of m-AMSA to cellular loci on which toxic effects are not exerted.

ExcerptReferenceRelevance
" These data, together with reports indicating a protective effect of ruthenium red against vinblastine and anthracycline toxicity, suggest that the dye promotes tight binding of m-AMSA and other agents to cellular loci on which toxic effects are not exerted."( Effects of ruthenium red on accumulation and cytotoxicity of m-AMSA, vinblastine and daunorubicin in leukemia cells.
Kessel, D; Wilberding, C, 1984
)
0.89
"0 mM, suggesting that the ruthenium species are significantly less toxic than Na(2)[Fe(CN)(5)(NO)] (SNP) species."( Hypotensive properties and acute toxicity of trans-[Ru(NH(3))(4)P(OEt)(3)(NO)](PF(6))(3), a new nitric oxide donor.
de Barros, BF; Franco, DW; Haun, M; Krieger, MH; Tfouni, E; Toledo, JC; Torsoni, AS, 2002
)
0.61
" The development of new antineoplastic medications demands adequate knowledge in order to avoid inefficient or toxic treatments."( The ruthenium complex cis-(dichloro)tetraammineruthenium(III) chloride presents selective cytotoxicity against murine B cell lymphoma (A-20), murine ascitic sarcoma 180 (S-180), human breast adenocarcinoma (SK-BR-3), and human T cell leukemia (Jurkat) tum
Dos Santos, WB; Goulart, LR; Hamaguchi, A; Homsi-Brandenburgo, MI; Nomizo, A; Pavanin, LA; Silveira-Lacerda, Ede P; Soares, AM; Vilanova-Costa, CA, 2010
)
0.92
" In addition, it was shown that Au(I) treatment generally caused more adverse effects than Ru(II) treatment in a dose-dependent manner."( Evaluation of reproductive toxicity in male rats treated with novel synthesized ruthenium(II) and gold(I)-NHC complexes.
Beytur, A; Ciftci, O; Ozdemir, I; Vardi, N, 2012
)
0.61
" In-vitro studies have indicated that this photosensitizer is toxic to melanoma cells when irradiated with low energy light; however, it is nontoxic to normal cells under similar conditions."( Toxicity and localization studies of a potential photodynamic therapy agent in Drosophila.
Kango-Singh, M; Stroh, C; Swavey, S; Yoho, J, 2014
)
0.4
" Good activity against Mycobacterium tuberculosis was maintained after the incorporation of the compounds into the nanostructured lipid system, while the cytotoxicity decreased dramatically, in some cases up to 20 times less toxic than the unencapsulated drug."( Nanostructured lipid systems as a strategy to improve the in vitro cytotoxicity of ruthenium(II) compounds.
Batista, AA; Chorilli, M; da Silva, MM; da Silva, PB; de Freitas, ES; de Oliveira Lopes, E; Leite, CQ; Pavan, FR, 2014
)
0.63
"We report DNA cleavage by ruthenium(II) arene anticancer complex [(η(6)-p-terp)Ru(II)(en)Cl](+) (p-terp=para-terphenyl, en=1,2-diaminoethane, complex 1) after its photoactivation by UVA and visible light, and the toxic effects of photoactivated 1 in cancer cells."( Photo-induced DNA cleavage and cytotoxicity of a ruthenium(II) arene anticancer complex.
Brabec, V; Kasparkova, J; Pracharova, J; Sadler, PJ; Stepankova, J, 2016
)
0.99
" The in vivo toxicological assessment performed on zebrafish embryos revealed that complexes (1) and (2) did not present embryotoxic or toxic effects during embryonic and larval development showing that they are promising new prototypes of safer and more effective drugs for triple negative breast cancer treatment."( In vitro cytotoxicity and in vivo zebrafish toxicity evaluation of Ru(ii)/2-mercaptopyrimidine complexes.
Batista, AA; Deflon, VM; Ellena, J; Ferreira, AG; Goveia, RM; Grisolia, CK; Lima, AP; Mello-Andrade, F; Oliveira, KM; Pereira, LR; Pires, WC; Rezende, MRM; Silva, MM; Silveira-Lacerda, EP; Velozo-Sá, VS, 2019
)
0.51
"Under the experimental conditions of this study, TM85 is less toxic than cisplatin, induces similar tumour reduction and avoids the formation of metastatic foci."( Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools.
Gano, L; Garcia, MH; Gonçalves, MS; Jorge, TF; Marques, F; Martins, M; Matos, AP; Morais, TS; Pinheiro, T; Tomaz, AI; Tortosa, F; Valente, A, 2019
)
0.51
" Additional tests using healthy MCF 10A cells showed that complexes II-IV were three- to sixfold less toxic than cisplatin, which suggested that complex IV was selective against cancer cells."( Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Carneiro, ZA; Carvalho, I; da Silva, RS; de Carvalho, MR; de Souza, GA; Ferreira, LP; Formiga, ALB; Gaspari, APS; Pernomian, L; Ramos, LCB, 2021
)
0.85

Pharmacokinetics

ExcerptReferenceRelevance
" This method has been successfully applied to a pharmacokinetic study in human urine after oral administration of AM."( Pharmacokinetics of amoxicillin in human urine using online coupled capillary electrophoresis with electrogenerated chemiluminescence detection.
Deng, B; Kang, Y; Li, L; Shi, A, 2008
)
0.35
"The relatively non-toxic family of cucurbit[n]uril, Q[n], have shown considerable potential in vitro as drug delivery agents, with only a few examples of pharmacokinetic (PK) studies for drug⊂Q[n]."( Probing the pharmacokinetics of cucurbit[7, 8 and 10]uril: and a dinuclear ruthenium antimicrobial complex encapsulated in cucurbit[10]uril.
Collins, JG; Day, AI; Feterl, M; Gorle, AK; Keene, FR; Kinobe, R; Li, F; Ranson, M; Vine, KL; Warner, JM, 2017
)
0.69

Compound-Compound Interactions

ExcerptReferenceRelevance
" The resolution-adapted all-atom and coarse-grained water model, in which an all-atom structural description of the entire system is maintained during the simulations, is combined with the ab initio quantum mechanics and molecular mechanics method."( Quantum Mechanics/Molecular Mechanics Method Combined with Hybrid All-Atom and Coarse-Grained Model: Theory and Application on Redox Potential Calculations.
Shen, L; Yang, W, 2016
)
0.43
" Importantly, C2 showed synergistic anticancer effect in combination with cisplatin and Vitamin C to further inhibit cell growth which suggested the potential role of C2 in cancer therapy."( Monofunctional dimetallic Ru(η6-arene) complexes inhibit NOTCH1 signaling pathway and synergistically enhance anticancer effect in combination with cisplatin or vitamin C.
Ali, A; Chi, H; Hao, H; Liu, Z; Lv, Z; Rahman, FU; Wang, N; Zhang, Y; Zhang, Z; Zhao, X, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" For the estimation of the bioavailability and the intestinal absorption from solid food, materials are required which have been intrinsically labelled with the chosen stable tracer, since the use of an extrinsic label may lead to erroneous results."( Biokinetic studies in humans with stable isotopes as tracers. Part 1: A methodology for incorporation of trace metals into vegetables.
Giussani, A; Heinrichs, U; Roth, P; Schramel, P; Wendler, I; Werner, E, 1998
)
0.3
" The basal cytosolic NO concentration ([NO]c) is lower in 2K-1C than in 2K cells, and the bioavailability of the NO released from TERPY is larger in 2K than in 2K-1C VSMCs."( Vitamin C improves the effect of a new nitric oxide donor on the vascular smooth muscle from renal hypertensive rats.
Bendhack, LM; da Silva, RS; Laurindo, FR; Lima, RG; Lunardi, CN; Rodrigues, GJ; Santos, CX, 2008
)
0.35
" A growing amount of evidence supports the possibility that increased NO inactivation by excess O2- may account for the decreased NO bioavailability and vascular dysfunction in hypertension."( New nitric oxide donors based on ruthenium complexes.
Bendhack, LM; da Silva, RS; Lunardi, CN, 2009
)
0.63
" The influence of the protein binding on the bioavailability of the prospective drugs, namely on the transport by blood plasma and uptake by cells is also discussed."( Transport of therapeutic vanadium and ruthenium complexes by blood plasma components.
Pessoa, JC; Tomaz, I, 2010
)
0.63
" As a consequence, the development of NO donors or scavengers for regulation of its concentration and bioavailability in vivo is required."( Tailoring NO donors metallopharmaceuticals: ruthenium nitrosyl ammines and aliphatic tetraazamacrocycles.
Doro, FG; Figueiredo, LE; Franco, DW; Metzker, G; Pereira, JC; Tfouni, E, 2010
)
0.62
"We report herein a systematic study on interactions of organometallic ruthenium(II) anticancer complex [(η(6)-arene)Ru(en)Cl](+) (arene = p-cymene (1) or biphenyl (2), en = ethylenediamine) with human transferrin (hTf) and the effects of the hTf-ligation on the bioavailability of these complexes with cisplatin as a reference."( Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.
Guo, W; Li, X; Luo, Q; Wang, F; Xiong, S; Zhao, Y; Zheng, W, 2013
)
0.87
" As a consequence, direct coordination to the protein is inhibited, which is expected to increase the bioavailability of the complexes, thus potentially leading to improved anticancer activity."( Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Chard, RA; Jang, T; Walsby, CJ; Webb, MI; Wong, EW; Wong, MQ; Wu, B; Yapp, DT, 2013
)
0.39
" Furthermore, the nitric oxide released by TERPY reacts with reactive oxygen species, decreasing their bioavailability in spontaneously hypertensive rats."( Mechanisms underlying the hypotensive and vasodilator effects of Ru(terpy)(bdq)NO](3+), a nitric oxide donor, differ between normotensive and spontaneously hypertensive rats.
Antoniali, C; Bendhack, LM; da Silva, RS; Graton, ME; Munhoz, FC; Nakamune, AC; Perassa, LA; Pereira, AA; Potje, SR; Sumida, DH, 2014
)
0.4
"NO donors are compounds that release NO that can be used when the endogenous NO bioavailability is impaired."( Hypotensive effect and vascular relaxation in different arteries induced by the nitric oxide donor RuBPY.
Andrade, FA; Araújo, AV; Bendhack, LM; da Silva, RS; Paulo, M; Pereira, AC; Silva, BR; Vercesi, JA, 2017
)
0.46
" Increased bioavailability and cell permeability of Ru-thio-chrysin compared to chrysin were found to be the basis for its enhanced activity."( Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacy.
Alzahrani, EMS; Attina, A; Gibbins, J; Greco, F; Javed, M; Kabova, E; Osborn, HMI; Pothi, R; Ravishankar, D; Salamah, M; Shankland, K; Strohfeldt, K; Vaiyapuri, R; Vaiyapuri, S; Vallance, TM; Williams, HF, 2017
)
1.9
"CHS-828 (N-(6-(4-chlorophenoxy)hexyl)-N'-cyano-N″-4-pyridyl guanidine) is an anticancer agent with low bioavailability and high systemic toxicity."( Photolabile ruthenium complexes to cage and release a highly cytotoxic anticancer agent.
Renfrew, AK; Wei, J, 2018
)
0.86
" However, the drawbacks of curcumin such as poor stability and bioavailability seriously limited its application in drug development."( Orientation-Inspired Perspective on Molecular Inhibitor of Tau Aggregation by Curcumin Conjugated with Ruthenium(II) Complex Scaffold.
Hu, X; Liu, W; Shi, S; Tu, Y; Yao, T; Zhou, L, 2020
)
0.77
" The poor bioavailability and quick metabolism of such natural compounds require new investigative methods to improve their stability in the organisms."( Antiproliferative Ruthenium Complexes Containing Curcuminoid Ligands Tested In Vitro on Human Ovarian Tumor Cell Line A2780, towards Their Capability to Modulate the NF-
Achimaş-Cadariu, P; Fischer-Fodor, E; Kubelac, PM; Leskovská, J; Markuliak, M; Miklášová, N; Valentová, J, 2022
)
1.06

Dosage Studied

Na2[[trans-RuCl4(Me2SO)]2(mu-etbipy)] (4) was as effective as NAMI-A in reducing the spontaneous metastases at a dosage which is about 3 moles of ruthenium.

ExcerptRelevanceReference
" Because of the rapid fall-off radiation dose it is possible to deliver a high dosage to the tumor without danger of radiogenic damage to the whole globe."( beta-Irradiation of retinoblastoma with 106Ru/106Rh applicators.
Lommatzsch, P, 1977
)
0.26
" HInd[RuInd2Cl4(N2)] showed high efficacy at the highest dosage of 13 mg/kg, reaching a T/C value of 27% combined with 0% mortality versus 15% in the control group."( Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats.
Berger, MR; Keppler, BK; Seelig, MH, 1992
)
0.56
" Close analysis of the dose-response curves revealed a biphasic pattern, indicative of the presence of two substrates of the Ca-release channel, displaying high- and low-affinity binding sites for the inhibitors."( Rapid kinetic analysis of the calcium-release channels of skeletal muscle sarcoplasmic reticulum: the effect of inhibitors.
Calviello, G; Chiesi, M, 1989
)
0.28
"This paper describes the development of a stable pharmaceutical dosage form for NAMI-A, a novel antimetastatic ruthenium complex, for Phase I testing."( Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
Beijnen, JH; Bouma, M; Bult, A; Flaibani, A; Kettenes-van den Bosch, JJ; Nuijen, B; Perbellini, A; Sava, G; Talsma, H; van Steenbergen, MJ, 2002
)
0.75
" The signal generation based on ECL resulted in an exponential dose-response pattern and the analyte detection limit of 2 ng/ml was approximately 10-fold more sensitive than that obtained from a conventional system."( Development of a membrane strip immunosensor utilizing ruthenium as an electro-chemiluminescent signal generator.
Cho, JH; Choi, JW; Kim, MJ; Lee, CW; Oh, HI; Paek, SH; Yoon, CH, 2003
)
0.57
" The current signal of the released liposomal Ru(NH(3))(6)(3+) was measured using square wave voltammetry, yielding a sigmoidally shaped dose-response curve whose linear portion was over the range from 1 to 10(6) fmol."( Attomole DNA electrochemical sensor for the detection of Escherichia coli O157.
Ho, JA; Liao, WC, 2009
)
0.35
" The photochemical strategy has the advantages that it allows for precise control of the timing, location, and dosage for the targeted delivery of a bioactive agent."( Metal complexes as photochemical nitric oxide precursors: potential applications in the treatment of tumors.
Ford, PC; Ostrowski, AD, 2009
)
0.35
" Half-maximum inhibitory concentrations of 2 and 4 with regard to A549 cells at 24 h were determined on the basis of the dose-response curves derived from real-time cell adhesion impedance measurements and were shown to be in the same range as those determined for KP1019 and NAMI-A using the same method."( X-ray fluorescence imaging of single human cancer cells reveals that the N-heterocyclic ligands of iodinated analogues of ruthenium anticancer drugs remain coordinated after cellular uptake.
Aitken, JB; Antony, S; Brown, T; Harris, HH; Lai, B; Spiccia, L; Vogt, S, 2013
)
0.6
" The increase in Ru/CeO2 dosage led to a progressive enhancement in the oxidation rate of BP by permanganate at neutral pH."( Ruthenium nanoparticles supported on CeO2 for catalytic permanganate oxidation of butylparaben.
Bao, H; Guan, X; Huang, Y; Qiao, J; Sun, B; Wang, H; Zhang, J; Zhou, G, 2013
)
1.83
" Bacterial samples were dosed with a range of photosensitizer concentrations (0."( Photodynamic inactivation of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus with Ru(II)-based type I/type II photosensitizers.
Arenas, Y; Lilge, L; Mandel, A; McFarland, S; Monro, S; Shi, G, 2013
)
0.39
" Nanostructured lipid systems may potentiate the action of drugs by reducing the required dosage and side effects and improving the antimicrobial effects."( Nanostructured lipid systems as a strategy to improve the in vitro cytotoxicity of ruthenium(II) compounds.
Batista, AA; Chorilli, M; da Silva, MM; da Silva, PB; de Freitas, ES; de Oliveira Lopes, E; Leite, CQ; Pavan, FR, 2014
)
0.63
" Although Ru(III) could catalyze permanganate oxidation of aniline effectively, dosing homogeneous Ru(III) into water would lead to a second pollution."( Ru(III) catalyzed permanganate oxidation of aniline at environmentally relevant pH.
Guan, X; Wang, H; Zhang, J; Zhang, Y, 2014
)
0.4
" Finally, the in vivo mice bearing A549 xenografts, Ru1 dosed at 10 or 20 mg/kg significantly inhibited tumor growth."( The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex.
Cai, K; Chen, J; Chen, L; Dongye, G; Feng, R; Jie, X; Li, B; Li, G; Lun, K; Peng, F; Xu, B; Zeng, Q, 2016
)
0.65
" Additionally, realizing the multiple vein passage of several PSs through dosing could be a challenge in clinical treatment."( Crossfire for Two-Photon Photodynamic Therapy with Fluorinated Ruthenium (II) Photosensitizers.
Chao, H; Huang, H; Huang, J; Ji, L; Qiu, K; Song, C; Wang, H; Wang, J; Wang, L; Zhu, H, 2017
)
0.69
"The Ru(ii) complex of an imidazole-mesalazine Schiff base is a unique example showing growth inhibition of 3D-colon cancer stem cell spheroids and bulk colon cancer cells at lower dosage than salinomycin or oxaliplatin."( Inhibition of 3D colon cancer stem cell spheroids by cytotoxic Ru
Acharya, S; Ghosh, S; Maji, M; Mukherjee, A; Parambil, ARU; Singh, S, 2020
)
0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
" One such limitation is inherent in the waterborne dosing regimen."( Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications.
Buckley, BT; Cooper, KR; Côrte-Real, L; Doherty, CL; Karas, BF; Terez, KR, 2022
)
1.01
" Thus, the use of Δ-enantiomer can significantly reduce the dosage needed for maximal treatment effect."( Unusual enantioselective cytoplasm-to-nucleus translocation and photosensitization of the chiral Ru(II) cationic complex via simple ion-pairing with lipophilic weak acid counter-anions.
Chao, XJ; Huang, CH; Huang, R; Li, Y; Tang, M; Yan, ZY; Zhu, BZ, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
iron group element atom
platinum group metal atom
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6,763)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990773 (11.43)18.7374
1990's161 (2.38)18.2507
2000's1640 (24.25)29.6817
2010's3262 (48.23)24.3611
2020's927 (13.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 76.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index76.89 (24.57)
Research Supply Index8.83 (2.92)
Research Growth Index5.43 (4.65)
Search Engine Demand Index141.45 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (76.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (0.10%)5.53%
Reviews268 (3.91%)6.00%
Case Studies15 (0.22%)4.05%
Observational1 (0.01%)0.25%
Other6,563 (95.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]